Gustavo A. Rosario Benitez

Array ( [id] => 14715611 [patent_doc_number] => 20190248869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => A UNIVERSAL PLATFORM FOR CAR THERAPY TARGETING A NOVEL ANTIGENIC SIGNATURE OF CANCER [patent_app_type] => utility [patent_app_number] => 16/336874 [patent_app_country] => US [patent_app_date] => 2017-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16336874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960643 [patent_doc_number] => 20190307799 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => ENGINEERED LYMPHOCYTES [patent_app_type] => utility [patent_app_number] => 16/335637 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12641304 [patent_doc_number] => 20180105599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => IMMUNOTHERAPEUTIC MOLECULES AND USES [patent_app_type] => utility [patent_app_number] => 15/708419 [patent_app_country] => US [patent_app_date] => 2017-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15708419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14624685 [patent_doc_number] => 20190225710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => MULTIMERS, TETRAMERS & OCTAMERS [patent_app_type] => utility [patent_app_number] => 16/333583 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13093369 [patent_doc_number] => 10066016 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => Single chain variable fragment CD3 binding proteins [patent_app_type] => utility [patent_app_number] => 15/704620 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 21850 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15782495 [patent_doc_number] => 10624950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins [patent_app_type] => utility [patent_app_number] => 15/704796 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 55 [patent_no_of_words] => 21047 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13182229 [patent_doc_number] => 10106617 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-23 [patent_title] => High affinity antibody antagonists of interleukin-13 receptor alpha 1 [patent_app_type] => utility [patent_app_number] => 15/697086 [patent_app_country] => US [patent_app_date] => 2017-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 18 [patent_no_of_words] => 25898 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15697086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702723 [patent_doc_number] => 20170362316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => Human Anti-IL-23 Antibodies, Compositions, Methods and Uses [patent_app_type] => utility [patent_app_number] => 15/694107 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15694107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13689641 [patent_doc_number] => 20170355775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => Monoclonal Antibodies and Methods of Use [patent_app_type] => utility [patent_app_number] => 15/685257 [patent_app_country] => US [patent_app_date] => 2017-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15685257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205853 [patent_doc_number] => 20180051080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/677651 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 13187 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15677651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14746795 [patent_doc_number] => 20190256571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/322897 [patent_app_country] => US [patent_app_date] => 2017-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12159148 [patent_doc_number] => 20180030414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-01 [patent_title] => 'ANTI CD4 ANTIBODIES TO PREVENT IN PARTICULAR GRAFT -VERSUS - HOST - DISEASE (GVHD)' [patent_app_type] => utility [patent_app_number] => 15/661035 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 27431 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219238 [patent_doc_number] => 20180057597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123' [patent_app_type] => utility [patent_app_number] => 15/654857 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 78262 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15654857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893851 [patent_doc_number] => 20190290691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE [patent_app_type] => utility [patent_app_number] => 16/310312 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11987787 [patent_doc_number] => 20170291943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'ANTI-INTERFERON GAMMA ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/628037 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 25337 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092561 [patent_doc_number] => 20170349655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION' [patent_app_type] => utility [patent_app_number] => 15/626637 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 28750 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15626637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15512799 [patent_doc_number] => 10562975 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-18 [patent_title] => CD6 antibody for treatment of T-cell mediated diseases or disorders [patent_app_type] => utility [patent_app_number] => 15/623729 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 45 [patent_no_of_words] => 14009 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454461 [patent_doc_number] => 20200040055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => DOSING REGIMEN FOR GP100-SPECIFIC TCR - ANTI-CD3 SCFV FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 16/305838 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9526 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309637 [patent_doc_number] => 20190144522 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => ANTI-CD7 CHIMERIC ANTIGEN RECEPTOR AND METHOD OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/307201 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12509364 [patent_doc_number] => 10000573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-19 [patent_title] => Monoclonal antibody and a method thereof [patent_app_type] => utility [patent_app_number] => 15/609625 [patent_app_country] => US [patent_app_date] => 2017-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 33 [patent_no_of_words] => 14548 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15609625 [rel_patent_id] =>[rel_patent_doc_number] =>)